Catalyst Biosciences receives FDA fast track designation for subcutaneous MarzAA for the treatment of episodic bleeding in haemophilia A or B with inhibitors

Catalyst Pharmaceuticals

2 December 2020 - Catalyst Biosciences today announced the U.S. FDA has granted fast track designation for marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously  administered next-generation engineered coagulation factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with haemophilia A or B with inhibitors that will enter a pivotal Phase 3 CRIMSON 1 trial this month.

The Phase 3 CRIMSON 1 trial is an open-label, global, multi-centre, randomised, cross-over study, designed to evaluate the safety and efficacy of MarzAA for on-demand treatment of spontaneous or traumatic bleeding episodes, in adolescents and adults with congenital haemophilia A or B with inhibitors, compared to the standard of care.

Read Catalyst Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Blood product , Fast track